The company has updated its digital ecosystem by merging its in-depth expertise on hyaluronic acid and regenerative medicine into the future and into scientific innovation, the driving force behind the evolution of the pharmaceutical sector.
The new Fidia Farmaceutici corporate website created by Isobar is online. The site not only introduces new graphics for a better browsing experience, but, most importantly, is an actual image restyling of the Italian Pharmaceutical Group who is a world leader in research and development, production and marketing of products based on hyaluronic acid and its derivatives.
The new digital platform supports the path towards modernisation and transformation started by the company and encompassed within Regenerate and Evolve, the new market positioning that aims to move perception from a pharmaceutical company with a strong Italian footprint to a global company able to capture market developments and actively participate in the transformation of the healthcare sector.
“Regenerate & Evolve is the beginning of a new narrative for the Fidia brand, projecting it towards the future while respecting our history – states Carlo Pizzocaro, President and CEO of Fidia Farmaceutici – These two words encompass and make tangible our commitment to therapeutic innovation. An ambitious positioning with which we want to send a strong signal to all our stakeholders, starting with our employees in every part of the world who can identify with this message.”
With over 1,100 patents on hyaluronic acid, mainly in the osteoarticular area, the company continues to “regenerate and evolve” investing in research and development to evaluate the application of the regenerative properties of this molecule to other therapeutic areas, and presenting itself to the world market with a renewed look that goes hand in hand with a clearer vision of the future of the sector.
The homepage of the new site highlights the sections dedicated to hyaluronic acid and regenerative medicine, where the properties and the different possibilities for application are described. In addition, great emphasis is given to research and development, the pivotal activities that allow for enriching the therapeutic offer with new solutions, and last, but not least, to the driving force that makes it all possible: people. Finally, an entire section is dedicated to news, which holds the history of press releases and a dedicated gallery with a collection of photos of the company and plants, all available for download.